Migraine frequency Number of attacks · patients with Raynaud's phenomenon
1 finding from 1 review
Duration of attacks · patients with Raynaud's phenomenon
1 finding from 1 review
Severity of attacks · patients with Raynaud's phenomenon
1 finding from 1 review
Pain intensity (0‐10cm visual analogue scale) · patients with Raynaud's phenomenon
1 finding from 1 review
Patient global Disability due to Raynaud's assessed on a 10‐cm visual analogue scale (0 = no disability, 10 = maximal disability) · patients with Raynaud's phenomenon
1 finding from 1 review
Withdrawals due to adverse events · patients with Raynaud's phenomenon
Calcium channel blockers showed no clear difference in number of withdrawals due to adverse events Number of participants… compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events Number of participants who died or withdrew and were hospitalized as a result of adverse effects of treatment · patients with Raynaud's phenomenon
1 finding from 1 review
Death or dependency at end of · people with acute ischemic stroke
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death at the end of treatment · people with acute ischemic stroke
Other calcium antagonists showed no clear difference in death at the end of treatment compared with placebo (low certainty).
1 finding from 1 review
Death at the end of · people with acute ischemic stroke
Other calcium antagonists showed no clear difference in death at the end of compared with placebo (low certainty).
1 finding from 1 review
Recurrence of stroke at the end of · people with acute ischemic stroke
1 finding from 1 review
Adverse events during treatment period · people with acute ischemic stroke
Other calcium antagonists showed no clear difference in adverse events during treatment period compared with placebo (low certainty).
1 finding from 1 review
Hypotension · people with acute ischemic stroke
Other calcium antagonists showed no clear difference in hypotension during treatment period compared with placebo (low certainty).
1 finding from 1 review
Systolic blood pressure · people with acute ischemic stroke
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Radiological failure · Children with extensive decay involving the dental pulp in primary teeth
Vitapex (calcium hydroxide/iodoform) showed no clear difference in radiological failure compared with calcium hydroxide (CH); GRADE not reported.
1 finding from 1 review
Radiological failure · Children with extensive decay involving the dental pulp in primary teeth
Vitapex (calcium hydroxide/iodoform) led to higher radiological failure compared with ZOE + calcium hydroxide + iodoform (MPRCF, unnamed product); GRADE not reported.
1 finding from 1 review
Clinical failure · Children with extensive decay involving the dental pulp in primary teeth
Vitapex (calcium hydroxide/iodoform) showed no clear difference in clinical failure compared with calcium hydroxide (CH); GRADE not reported.
1 finding from 1 review
Radiological failure · Children with extensive decay involving the dental pulp in primary teeth
Vitapex (calcium hydroxide/iodoform) showed no clear difference in radiological failure compared with sealapex (eugenol-free calcium hydroxide); GRADE not reported.
1 finding from 1 review
Clinical failure · Children with extensive decay involving the dental pulp in primary teeth
Vitapex (calcium hydroxide/iodoform) led to higher clinical failure compared with ZOE + calcium hydroxide + iodoform (MPRCF, unnamed product); GRADE not reported.
1 finding from 1 review
Clinical failure · Children with extensive decay involving the dental pulp in primary teeth
Vitapex (calcium hydroxide/iodoform) showed no clear difference in clinical failure compared with sealapex (eugenol-free calcium hydroxide); GRADE not reported.
1 finding from 1 review